US6838129B2 - Method and device for transporting an electrical charge - Google Patents
Method and device for transporting an electrical charge Download PDFInfo
- Publication number
- US6838129B2 US6838129B2 US10/296,226 US29622602A US6838129B2 US 6838129 B2 US6838129 B2 US 6838129B2 US 29622602 A US29622602 A US 29622602A US 6838129 B2 US6838129 B2 US 6838129B2
- Authority
- US
- United States
- Prior art keywords
- phase
- liquid crystalline
- smectic
- crystalline compound
- liquid crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 113
- 239000007788 liquid Substances 0.000 claims abstract description 104
- 239000004990 Smectic liquid crystal Substances 0.000 claims abstract description 85
- 239000004973 liquid crystal related substance Substances 0.000 claims abstract description 76
- 230000007704 transition Effects 0.000 claims abstract description 20
- 239000007787 solid Substances 0.000 claims abstract description 19
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 25
- 230000001747 exhibiting effect Effects 0.000 claims description 23
- 239000000758 substrate Substances 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 7
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000012071 phase Substances 0.000 description 108
- 239000000463 material Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- -1 poly(N-vinylcarbazole) Polymers 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- BVGPNXUAQMNNGI-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-decylpiperazine Chemical compound C1CN(CCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 BVGPNXUAQMNNGI-UHFFFAOYSA-N 0.000 description 5
- XFOCXAXAJSVEEA-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-octylpiperazine Chemical compound C1CN(CCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 XFOCXAXAJSVEEA-UHFFFAOYSA-N 0.000 description 5
- 0 [1*]C(=C)*Oc1ccc(N2CCN([2*])CC2)cc1 Chemical compound [1*]C(=C)*Oc1ccc(N2CCN([2*])CC2)cc1 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- VMKOFRJSULQZRM-UHFFFAOYSA-N 1-bromooctane Chemical compound CCCCCCCCBr VMKOFRJSULQZRM-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- YFRIBKKRVXLBGB-UHFFFAOYSA-N B[Sm] Chemical compound B[Sm] YFRIBKKRVXLBGB-UHFFFAOYSA-N 0.000 description 4
- 150000001350 alkyl halides Chemical class 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 3
- GZGAUYCYORDMNA-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-dodecylpiperazine Chemical compound C1CN(CCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 GZGAUYCYORDMNA-UHFFFAOYSA-N 0.000 description 3
- XZOFQOPMMDEQBC-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-undecylpiperazine Chemical compound C1CN(CCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 XZOFQOPMMDEQBC-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- UBOXGVDOUJQMTN-UHFFFAOYSA-N 1,1,2-trichloroethane Chemical compound ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- IAINMCMCBDAVNM-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)piperazine Chemical compound C1=CC(OCCCCCCCCC=C)=CC=C1N1CCNCC1 IAINMCMCBDAVNM-UHFFFAOYSA-N 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- HWWYDZCSSYKIAD-UHFFFAOYSA-N 3,5-dimethylpyridine Chemical compound CC1=CN=CC(C)=C1 HWWYDZCSSYKIAD-UHFFFAOYSA-N 0.000 description 2
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000012433 hydrogen halide Substances 0.000 description 2
- 229910000039 hydrogen halide Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- SMUQFGGVLNAIOZ-UHFFFAOYSA-N quinaldine Chemical compound C1=CC=CC2=NC(C)=CC=C21 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QVLAWKAXOMEXPM-UHFFFAOYSA-N 1,1,1,2-tetrachloroethane Chemical compound ClCC(Cl)(Cl)Cl QVLAWKAXOMEXPM-UHFFFAOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ADZOHHUPJVHILC-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-heptadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 ADZOHHUPJVHILC-UHFFFAOYSA-N 0.000 description 1
- XVFIJGWIUKDSCD-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-hexadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 XVFIJGWIUKDSCD-UHFFFAOYSA-N 0.000 description 1
- JVMIYZPNPOIMPS-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-nonylpiperazine Chemical compound C1CN(CCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 JVMIYZPNPOIMPS-UHFFFAOYSA-N 0.000 description 1
- ATVXLNDBFWNDIF-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-octadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 ATVXLNDBFWNDIF-UHFFFAOYSA-N 0.000 description 1
- UELFKGJMTHARBQ-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-pentadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 UELFKGJMTHARBQ-UHFFFAOYSA-N 0.000 description 1
- KYLQWBNFDDMNRF-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-tetradecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 KYLQWBNFDDMNRF-UHFFFAOYSA-N 0.000 description 1
- SWIVKPHUPUBFME-UHFFFAOYSA-N 1-(4-dec-9-enoxyphenyl)-4-tridecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCC=C)C=C1 SWIVKPHUPUBFME-UHFFFAOYSA-N 0.000 description 1
- FYBPCDBQKQUJAR-UHFFFAOYSA-N 1-(4-hept-6-enoxyphenyl)-4-hexadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 FYBPCDBQKQUJAR-UHFFFAOYSA-N 0.000 description 1
- VSSYJXOXLHCUAB-UHFFFAOYSA-N 1-(4-hept-6-enoxyphenyl)-4-nonylpiperazine Chemical compound C1CN(CCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 VSSYJXOXLHCUAB-UHFFFAOYSA-N 0.000 description 1
- LZLZITLQZANNOL-UHFFFAOYSA-N 1-(4-hept-6-enoxyphenyl)-4-octadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 LZLZITLQZANNOL-UHFFFAOYSA-N 0.000 description 1
- NAZJGXNQUIKBGM-UHFFFAOYSA-N 1-(4-hept-6-enoxyphenyl)-4-octylpiperazine Chemical compound C1CN(CCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 NAZJGXNQUIKBGM-UHFFFAOYSA-N 0.000 description 1
- LYXMUCFWAUFGDI-UHFFFAOYSA-N 1-(4-hept-6-enoxyphenyl)-4-pentadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 LYXMUCFWAUFGDI-UHFFFAOYSA-N 0.000 description 1
- PGFIVAANUCTVQS-UHFFFAOYSA-N 1-(4-hept-6-enoxyphenyl)-4-tetradecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 PGFIVAANUCTVQS-UHFFFAOYSA-N 0.000 description 1
- RZWYURNIKZMGRS-UHFFFAOYSA-N 1-(4-hept-6-enoxyphenyl)-4-tridecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 RZWYURNIKZMGRS-UHFFFAOYSA-N 0.000 description 1
- RFGPKLSCEXXYKT-UHFFFAOYSA-N 1-(4-hept-6-enoxyphenyl)-4-undecylpiperazine Chemical compound C1CN(CCCCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 RFGPKLSCEXXYKT-UHFFFAOYSA-N 0.000 description 1
- OHBJBEYCIACVNA-UHFFFAOYSA-N 1-(4-non-8-enoxyphenyl)-4-nonylpiperazine Chemical compound C1CN(CCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 OHBJBEYCIACVNA-UHFFFAOYSA-N 0.000 description 1
- DITZLNWCTSXFRJ-UHFFFAOYSA-N 1-(4-non-8-enoxyphenyl)-4-octadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 DITZLNWCTSXFRJ-UHFFFAOYSA-N 0.000 description 1
- OTYWVRCRHWQGAW-UHFFFAOYSA-N 1-(4-non-8-enoxyphenyl)-4-octylpiperazine Chemical compound C1CN(CCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 OTYWVRCRHWQGAW-UHFFFAOYSA-N 0.000 description 1
- UICUIQXQFWGHCA-UHFFFAOYSA-N 1-(4-non-8-enoxyphenyl)-4-pentadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 UICUIQXQFWGHCA-UHFFFAOYSA-N 0.000 description 1
- JDLYBBCFPLBBJK-UHFFFAOYSA-N 1-(4-non-8-enoxyphenyl)-4-tetradecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 JDLYBBCFPLBBJK-UHFFFAOYSA-N 0.000 description 1
- ZYTFGZWZGLJCKG-UHFFFAOYSA-N 1-(4-non-8-enoxyphenyl)-4-tridecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 ZYTFGZWZGLJCKG-UHFFFAOYSA-N 0.000 description 1
- VPLCGUZYJQQHMV-UHFFFAOYSA-N 1-(4-non-8-enoxyphenyl)-4-undecylpiperazine Chemical compound C1CN(CCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 VPLCGUZYJQQHMV-UHFFFAOYSA-N 0.000 description 1
- NPNVPJATRISVQZ-UHFFFAOYSA-N 1-(4-oct-7-enoxyphenyl)-4-octylpiperazine Chemical compound C1CN(CCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 NPNVPJATRISVQZ-UHFFFAOYSA-N 0.000 description 1
- UUYIJKYIIKONQG-UHFFFAOYSA-N 1-(4-oct-7-enoxyphenyl)-4-pentadecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 UUYIJKYIIKONQG-UHFFFAOYSA-N 0.000 description 1
- MBSRGENXONJONO-UHFFFAOYSA-N 1-(4-oct-7-enoxyphenyl)-4-tetradecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 MBSRGENXONJONO-UHFFFAOYSA-N 0.000 description 1
- AAGJYSHJWMBFOR-UHFFFAOYSA-N 1-(4-oct-7-enoxyphenyl)-4-tridecylpiperazine Chemical compound C1CN(CCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 AAGJYSHJWMBFOR-UHFFFAOYSA-N 0.000 description 1
- KZBGVVPAGPJFMW-UHFFFAOYSA-N 1-(4-oct-7-enoxyphenyl)-4-undecylpiperazine Chemical compound C1CN(CCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 KZBGVVPAGPJFMW-UHFFFAOYSA-N 0.000 description 1
- UAKDOTOODMIAAN-UHFFFAOYSA-N 1-(4-undec-10-enoxyphenyl)-4-undecylpiperazine Chemical compound C1CN(CCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 UAKDOTOODMIAAN-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 1
- PBLNBZIONSLZBU-UHFFFAOYSA-N 1-bromododecane Chemical compound CCCCCCCCCCCCBr PBLNBZIONSLZBU-UHFFFAOYSA-N 0.000 description 1
- IKPSIIAXIDAQLG-UHFFFAOYSA-N 1-bromoundecane Chemical compound CCCCCCCCCCCBr IKPSIIAXIDAQLG-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- ZDIBEDHSNMJYDF-UHFFFAOYSA-N 1-decyl-4-(4-hept-6-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 ZDIBEDHSNMJYDF-UHFFFAOYSA-N 0.000 description 1
- KYQUQFYCFMKXCE-UHFFFAOYSA-N 1-decyl-4-(4-non-8-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 KYQUQFYCFMKXCE-UHFFFAOYSA-N 0.000 description 1
- SKBNWFPZJVEDDZ-UHFFFAOYSA-N 1-decyl-4-(4-oct-7-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 SKBNWFPZJVEDDZ-UHFFFAOYSA-N 0.000 description 1
- JJSVKNQURFMNPM-UHFFFAOYSA-N 1-decyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 JJSVKNQURFMNPM-UHFFFAOYSA-N 0.000 description 1
- YNPRDPKSMYCPPW-UHFFFAOYSA-N 1-dodecyl-4-(4-hept-6-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 YNPRDPKSMYCPPW-UHFFFAOYSA-N 0.000 description 1
- OTUKUFCEHYOXRY-UHFFFAOYSA-N 1-dodecyl-4-(4-non-8-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 OTUKUFCEHYOXRY-UHFFFAOYSA-N 0.000 description 1
- RUKYPZLTQZWUQW-UHFFFAOYSA-N 1-dodecyl-4-(4-oct-7-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 RUKYPZLTQZWUQW-UHFFFAOYSA-N 0.000 description 1
- WGJKNUKQRZDKRB-UHFFFAOYSA-N 1-dodecyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 WGJKNUKQRZDKRB-UHFFFAOYSA-N 0.000 description 1
- QLABOZYVVZINMA-UHFFFAOYSA-N 1-heptadecyl-4-(4-hept-6-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCC=C)C=C1 QLABOZYVVZINMA-UHFFFAOYSA-N 0.000 description 1
- NGXNUZXYXQFRHF-UHFFFAOYSA-N 1-heptadecyl-4-(4-non-8-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 NGXNUZXYXQFRHF-UHFFFAOYSA-N 0.000 description 1
- DOIKKGDITJJDBN-UHFFFAOYSA-N 1-heptadecyl-4-(4-oct-7-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 DOIKKGDITJJDBN-UHFFFAOYSA-N 0.000 description 1
- RHZROVQYNFYTSV-UHFFFAOYSA-N 1-heptadecyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 RHZROVQYNFYTSV-UHFFFAOYSA-N 0.000 description 1
- UQKVDDDDZMJVDG-UHFFFAOYSA-N 1-hexadecyl-4-(4-non-8-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCC=C)C=C1 UQKVDDDDZMJVDG-UHFFFAOYSA-N 0.000 description 1
- HDZWAJGYWIKXNY-UHFFFAOYSA-N 1-hexadecyl-4-(4-oct-7-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 HDZWAJGYWIKXNY-UHFFFAOYSA-N 0.000 description 1
- XTXPZRUQFOFPPJ-UHFFFAOYSA-N 1-hexadecyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 XTXPZRUQFOFPPJ-UHFFFAOYSA-N 0.000 description 1
- ZBKDUUKNOVNDPA-UHFFFAOYSA-N 1-nonyl-4-(4-oct-7-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 ZBKDUUKNOVNDPA-UHFFFAOYSA-N 0.000 description 1
- IRCABXATKNNFDV-UHFFFAOYSA-N 1-nonyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 IRCABXATKNNFDV-UHFFFAOYSA-N 0.000 description 1
- XOFQZUBBXQRMJB-UHFFFAOYSA-N 1-octadecyl-4-(4-oct-7-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCC=C)C=C1 XOFQZUBBXQRMJB-UHFFFAOYSA-N 0.000 description 1
- SMOKLPBPEVNXHY-UHFFFAOYSA-N 1-octadecyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 SMOKLPBPEVNXHY-UHFFFAOYSA-N 0.000 description 1
- IHJMWWLAFLCTON-UHFFFAOYSA-N 1-octyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 IHJMWWLAFLCTON-UHFFFAOYSA-N 0.000 description 1
- WUXDSCHICPLMGE-UHFFFAOYSA-N 1-pentadecyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 WUXDSCHICPLMGE-UHFFFAOYSA-N 0.000 description 1
- HARBABKMRIWXJL-UHFFFAOYSA-N 1-tetradecyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 HARBABKMRIWXJL-UHFFFAOYSA-N 0.000 description 1
- KQKQORMNPFLZRC-UHFFFAOYSA-N 1-tridecyl-4-(4-undec-10-enoxyphenyl)piperazine Chemical compound C1CN(CCCCCCCCCCCCC)CCN1C1=CC=C(OCCCCCCCCCC=C)C=C1 KQKQORMNPFLZRC-UHFFFAOYSA-N 0.000 description 1
- JVVPJOMYWVYPOF-UHFFFAOYSA-N 10-bromodec-1-ene Chemical compound BrCCCCCCCCC=C JVVPJOMYWVYPOF-UHFFFAOYSA-N 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- HBNICUCGMMJTCX-UHFFFAOYSA-N 3,4,5,5a,6,7,8,9-octahydropyrido[1,2-c][1,3]diazepine Chemical compound C1=NCCCC2CCCCN21 HBNICUCGMMJTCX-UHFFFAOYSA-N 0.000 description 1
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- VJXRKZJMGVSXPX-UHFFFAOYSA-N 4-ethylpyridine Chemical compound CCC1=CC=NC=C1 VJXRKZJMGVSXPX-UHFFFAOYSA-N 0.000 description 1
- GPEOAEVZTOQXLG-UHFFFAOYSA-N 4-piperazin-1-ium-1-ylphenolate Chemical compound C1=CC(O)=CC=C1N1CCNCC1 GPEOAEVZTOQXLG-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OSPXEHBRDPZVQJ-UHFFFAOYSA-N C1=CC2=C(C=C1)C=NC=C2.C1=CC2=C(C=C1)C=NN=C2.C1=CC2=C(C=C1)N=CC=C2.C1=CC2=C(C=C1)N=CC=N2.C1=CC2=C(C=C1)N=CN=C2.C1=CC2=C(C=C1)N=NC=C2.C1=CC2=C(N=C1)N=CC=C2.C1=CC=CC=C1.C1=CC=NC=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CN=NC=C1.C1=NC=NC2=C1N=CC=N2.C1CCCCC1.C1COCOC1.C1COCSC1.C1CSCSC1.[HH] Chemical compound C1=CC2=C(C=C1)C=NC=C2.C1=CC2=C(C=C1)C=NN=C2.C1=CC2=C(C=C1)N=CC=C2.C1=CC2=C(C=C1)N=CC=N2.C1=CC2=C(C=C1)N=CN=C2.C1=CC2=C(C=C1)N=NC=C2.C1=CC2=C(N=C1)N=CC=C2.C1=CC=CC=C1.C1=CC=NC=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CN=NC=C1.C1=NC=NC2=C1N=CC=N2.C1CCCCC1.C1COCOC1.C1COCSC1.C1CSCSC1.[HH] OSPXEHBRDPZVQJ-UHFFFAOYSA-N 0.000 description 1
- ATLMFJTZZPOKLC-UHFFFAOYSA-N C70 fullerene Chemical compound C12=C(C3=C4C5=C67)C8=C9C%10=C%11C%12=C%13C(C%14=C%15C%16=%17)=C%18C%19=C%20C%21=C%22C%23=C%24C%21=C%21C(C=%25%26)=C%20C%18=C%12C%26=C%10C8=C4C=%25C%21=C5C%24=C6C(C4=C56)=C%23C5=C5C%22=C%19C%14=C5C=%17C6=C5C6=C4C7=C3C1=C6C1=C5C%16=C3C%15=C%13C%11=C4C9=C2C1=C34 ATLMFJTZZPOKLC-UHFFFAOYSA-N 0.000 description 1
- 239000004986 Cholesteric liquid crystals (ChLC) Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SVYKKECYCPFKGB-UHFFFAOYSA-N N,N-dimethylcyclohexylamine Chemical compound CN(C)C1CCCCC1 SVYKKECYCPFKGB-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 239000004988 Nematic liquid crystal Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004974 Thermotropic liquid crystal Substances 0.000 description 1
- AAYORPDAWNMKQG-UHFFFAOYSA-N [H]N1CCCC1.[H]N1CCCCC1.[H]N1CCN([H])C1.[H]N1CCN([H])CC1 Chemical compound [H]N1CCCC1.[H]N1CCCCC1.[H]N1CCN([H])C1.[H]N1CCN([H])CC1 AAYORPDAWNMKQG-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940075397 calomel Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 1
- XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000012769 display material Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000005525 hole transport Effects 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- DMQSHEKGGUOYJS-UHFFFAOYSA-N n,n,n',n'-tetramethylpropane-1,3-diamine Chemical compound CN(C)CCCN(C)C DMQSHEKGGUOYJS-UHFFFAOYSA-N 0.000 description 1
- CIXSDMKDSYXUMJ-UHFFFAOYSA-N n,n-diethylcyclohexanamine Chemical compound CCN(CC)C1CCCCC1 CIXSDMKDSYXUMJ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical group C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920003227 poly(N-vinyl carbazole) Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- ODHXBMXNKOYIBV-UHFFFAOYSA-N triphenylamine Chemical class C1=CC=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 ODHXBMXNKOYIBV-UHFFFAOYSA-N 0.000 description 1
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical group OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/52—Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives with special physical aspect: solvents, solid particles
- C09K19/58—Dopants or charge transfer agents
- C09K19/582—Electrically active dopants, e.g. charge transfer agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
- C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
- C09K19/3483—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a non-aromatic ring
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
- H10K85/731—Liquid crystalline materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2323/00—Functional layers of liquid crystal optical display excluding electroactive liquid crystal layer characterised by chemical composition
Definitions
- the present invention relates to novel electrical charge transport methods and charge transport devices using liquid crystalline compounds.
- anthracene derivatives As conventional charge transport materials, anthracene derivatives, anthraquinone derivatives, imidazole derivatives, styryl derivatives, hydrazine derivatives, triphenylamine compounds, poly(N-vinylcarbazole), oxadiazole, and other compounds are known.
- Liquid crystalline compounds are applied, as display materials, to various apparatus such as clocks, electronic desk-top calculators, television sets, personal computers, and cellular phones.
- Liquid crystalline substances are categorized as thermotropic liquid crystals and lyotropic liquid crystals based on their phase transition means. From the viewpoint of molecular alignment, these liquid crystals are categorized into three groups, namely smectic liquid crystals, nematic liquid crystals, and cholesteric liquid crystals.
- the liquid crystals have a synonym of anisotropic liquids and are optically anisotropic as in optically uniaxial crystals. Orthoscopic observation is observation performed between regular crossed nicols and is useful for the identification of the types of liquid crystals or for the determination of transition temperatures of liquid crystal phases.
- the individual liquid crystals show characteristic birefringent optical patterns upon the orthoscopic observation, and the smectic crystals are further categorized as A, B, C, D, E, F, G and other smectic phases.
- liquid crystalline compounds having a smectic liquid crystal phase are capable of transporting charges and have proposed charge transport materials using these liquid crystalline compounds. They have proposed, for example, a liquid crystalline charge transport material exhibiting smectic liquid crystallinity and having a reduction potential with respect to a standard calomel electrode (SCE) in the range of from ⁇ 0.3 to ⁇ 0.6 (V vs. SCE) (Japanese Patent Laid open No. 09-316442), a liquid crystalline charge transport material comprising a liquid crystalline compound exhibiting a smectic phase having self-orientation properties and a predetermined amount of fullerene C70 capable of sensitizing (Japanese Patent Laid open No.
- a high polymer membrane comprising a liquid crystalline charge transport material dispersed therein in which a liquid crystalline compound exhibiting a smectic phase is dispersed in an organic polymeric matrix
- Japanese Patent Laid open No. 11-172118 Japanese Patent Laid open No. 11-172118
- a liquid crystalline charge transport material comprising a mixture containing a smectic liquid crystalline compound
- Japanese Patent Laid open No. 11-199871 Japanese Patent Laid open No. 11-199871
- a liquid crystalline charge transport material having smectic liquid crystallinity and an electron mobility or electron hole mobility of not less than 1 ⁇ 10 ⁇ 5 cm 2 /v.s Japanese Patent Laid open No.
- liquid crystalline charge transport material comprising a smectic liquid crystalline compound having, in one molecule, a functional group capable of forming a new intermolecular or intramolecular bond and a functional group capable of transporting holes and/or electron charges
- Japanese Unexamined Patent Application Publication No. 11-209761 Japanese Unexamined Patent Application Publication No. 11-209761
- the above-proposed smectic liquid crystalline compounds are smectic liquid crystalline compounds having 6 ⁇ -electron aromatic rings such as benzene ring, pyridine ring, pyrimidine ring, pyridazine ring, pyrazine ring, tropolone ring, and compounds having 10 ⁇ -electron aromatic rings such as naphthalene ring, azulene ring, benzofuran ring, indole ring, indazole ring, benzothiazole ring, benzoxazole ring, benzimidazole ring, quinoline ring, isoquinoline ring, quinazoline ring, quinoxaline ring, and compounds having 14 ⁇ -electron aromatic rings such as phenanthrene ring, anthracene ring, and others.
- 6 ⁇ -electron aromatic rings such as benzene ring, pyridine ring, pyrimidine ring, pyrida
- These compounds are used for charge transporting in a smectic A liquid crystal phase.
- Such charge transporting with the aid of smectic A phase is charge transporting using spread of a conjugated system in the molecule. Accordingly, none of these compounds can exhibit excellent charge transporting capability unless they are excited by, for example, light. In addition, they have a low current density, at most on the order of nanoamperes per square centimeter.
- the present invention has been accomplished in view of these conventional technologies, and an object of the present invention is to provide a method and device for transporting an electric charge which exhibit a high current density and have excellent charge transporting capability by applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, which liquid crystalline compound exhibits a smectic B phase as a liquid crystal phase.
- Another object of the present invention is to provide a charge transport method and a charge transport device which exhibit a high current density and have excellent charge transporting capability by applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase induced by temperature depression, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase.
- the first invention of the present invention is a charge transport method comprising the step of applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, which liquid crystalline compound exhibits the smectic B phase as a liquid crystal phase.
- the second invention of the present invention is a charge transport method comprising the step of applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase.
- the liquid crystalline compounds are preferably smectic liquid crystalline compounds each having a strongly basic moiety in their skeleton.
- the third invention of the present invention is a charge transport device comprising a pair of substrates each having an electrode; a liquid crystal layer sandwiched between the substrates and comprising a liquid crystalline compound exhibiting a smectic B phase as a liquid crystal phase; and means for applying a voltage to the liquid crystalline compound in a smectic B liquid crystal phase to thereby transport charges through the liquid crystal layer.
- a fourth invention of the present invention is a charge transport device comprising a pair of substrates each having an electrode; a liquid crystal layer sandwiched between the substrates and comprising a liquid crystalline compound exhibiting a smectic phase as a liquid crystal phase; and means for applying a voltage to the liquid crystalline compound in a solid state formed as a result of phase transition from the smectic phase to thereby transport charges through the liquid crystal layer.
- FIG. 1 is a schematic diagram of a charge transport device as an embodiment of the present invention.
- FIG. 2 is a schematic diagram of a charge transport device as another embodiment of the present invention.
- FIG. 3 is an X-ray chart of 1-[4-(9-decenyloxy)phenyl]-4-octylpiperazine obtained in Reference Example 1.
- FIG. 4 is a graph showing dark currents of a liquid crystal in smectic B phase in Example 1.
- FIG. 5 is a graph showing changes in current with voltage in the liquid crystal in the smectic B phase in Example 1.
- FIG. 6 is a graph showing dark currents of a liquid crystal in a isotropic liquid phase in Example 1.
- FIG. 7 is a graph showing changes in current with voltage in the liquid crystal in the isotropic liquid phase in Example 1.
- 1 a and 1 b are glass substrates
- 2 a and 2 b are electrodes
- 4 is a spacer
- 3 and 13 are liquid crystal layers
- 5 is a voltage application means, respectively.
- the charge transport method according to the first invention of the present invention comprises the step of applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, which liquid crystalline compound exhibits the smectic B phase as a liquid crystal phase.
- the charge transport method of the present invention has been accomplished based on the following novel findings. Specifically, when a voltage is applied to a liquid crystalline compound in a smectic B liquid crystal phase where the liquid crystalline compound exhibits the smectic B phase as a liquid crystal phase, the liquid crystalline compound shows higher charge transporting capability only by the application of a voltage without photo-induced excitation. Particularly, when a liquid crystalline compound having a strongly basic moiety in its skeleton is used, liquid crystal molecules each having the strongly basic moiety, namely a moiety with high electron density are overlapped in the smectic B liquid crystal phase where molecules overlap densely. By this configuration, the method can transport charges at a high current density at least on the order of microamperes per square centimeter without the wide spreading of a conjugated system as in a smectic A phase, in contrast to conventional charge transport materials.
- Liquid crystals for use in the charge transport method of the present invention are not specifically limited as long as they are liquid crystalline compounds exhibiting smectic B phase as a liquid crystal phase, and known compounds can be used.
- Such liquid crystalline compounds exhibiting a smectic B phase can be whichever liquid crystalline compound exhibits a smectic B phase alone as a liquid crystal phase or those exhibiting other smectic phase(s) in addition to the smectic B phase.
- the liquid crystalline compounds may be those exhibiting A phase and B phase, those exhibiting A phase, B phase, and C phase, and any other liquid crystalline compounds exhibiting smectic B phase.
- the liquid crystalline compounds may also be polymeric liquid crystalline compounds exhibiting smectic B phase.
- liquid crystalline compounds having a smectic B phase for use in the charge transport method of the present invention, preference is given to those having a strongly basic moiety in their skeletons, of which those having a monocyclic heterocycle in its skeleton are especially preferred.
- Preferred monocyclic heterocycles include, for example, piperidine, piperazine, pyridine, pyridazine, pyrimidine, and pyrazine.
- liquid crystalline compounds having piperazine in their skeletons are especially preferred.
- piperazine-containing liquid crystalline compounds represented by the following general formula (1) are more preferred.
- R 1 is a hydrogen atom or a methyl group.
- R 2 is a straight- or branched-chain alkyl group containing from 1 to 22 carbon atoms, such as methyl group, ethyl group, propyl group, butyl group, octyl group, decyl group, dodecyl group, and octadecyl group. Among them, those containing from 8 to 14 carbon atoms are especially preferred.
- A is an alkylene group, and preference is given to those containing from 6 to 10 carbon atoms.
- alkylene groups are methylene groups, ethylene groups, trimethylene groups, tetramethylene groups, pentamethylenes groups, ethylethylene groups, propylene groups, butylene groups, hexylene groups, octadecylene groups, nonylene groups, decylene groups, and dodecylene groups.
- Preferred examples of the piperazine-containing liquid crystalline compounds represented by general formula (1) include:
- the piperazine-containing liquid crystalline compounds represented by general formula (1) can be prepared, for example, according to the following reaction formulae (1) and (2): Reaction Formula (1) Reaction Formula (2) wherein R 1 and R 2 have the same meanings as defined above; X is a halogen atom such as a chlorine atom and fluorine atom; and M is an alkali metal such as potassium and sodium.
- a piperazine derivative represented by general formula (4) can be easily obtained by reacting a halide represented by general formula (2) with an alcoholate represented by general formula (3) in an organic solvent.
- the molar ratio of the alcoholate of general formula (3) to the halide of general formula (2) is generally from 1 to 4, and preferably from 1 to 2.
- the reaction temperature is generally from 0° C. to 100° C. and preferably from 10° C. to 40° C.
- the reaction time is generally from 1 to 50 hours and preferably from 10 to 30 hours.
- Reaction solvents are not specifically limited, as long as they can dissolve the halide and alcoholate and are inert, and include, for example, toluene, xylenes, benzene, and other aromatic hydrocarbons; 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1,1,2-tetrachloroethane, 1,1,2,2-tetrachloroethane, and other haloalkanes; and N,N-dimethylformamide. Each of these solvents can be used alone or in combination.
- the piperazine derivative represented by general formula (4) is obtained according to a conventional purification procedure such as extraction and recrystallization.
- a piperazine-containing liquid crystalline compound represented by general formula (1) can be easily prepared by reacting the piperidine derivative represented by general formula (4) with an alkyl halide represented by general formula (5) in an organic solvent in the presence of a base.
- the molar ratio of the alkyl halide represented by general formula (5) to the piperidine derivative represented by general formula (4) is generally from 1 to 4 and preferably from 1 to 2.
- the reaction temperature is generally from 0° C. to 100° C. and preferably from 20° C. to 80° C.
- the reaction time is generally from 1 to 60 hours and preferably from 24 to 50 hours.
- the base examples include, but are not limited to, sodium hydroxide, sodium carbonate, sodium hydrogencarbonate, potassium hydroxide, potassium carbonate, potassium hydrogencarbonate, calcium hydroxide, calcium carbonate, and other inorganic bases; trimethylamine, N,N-dimethylcyclohexylamine, N,N-diethylcyclohexylamine, N,N-dimethylbenzylamine, N,N′-dimethylpiperazine, N,N-dimethylaniline, N,N-diethylaniline, N,N,N′, N′-tetramethyl-1,3-propanediamine, pyridine, ⁇ -picoline, ⁇ -picoline, ⁇ -picoline, 4-ethylmorpholine, triethylenediamine, 1,3-diazabicyclo[5,4,0]undecene, 1,8-diazabicyclo[5,4,0]-7-undecene, N-ethylpiperidine, quinoline,
- the amount of the base has only to be an amount sufficient to capture a hydrogen halide formed as by-product and is generally from 1 to 6 times, preferably from 1 to 3 times, and more preferably from 1.1 to 2 times the stoichiometric amount of the by-produced hydrogen halide.
- Reaction solvents for use herein are not specifically limited, as long as they can dissolve the alkyl halide and the piperidine derivative represented by general formula (4) and are inert, and include, for example, dioxane, tetrahydrofuran, dibutyl ether, and other ethers; acetonitrile, propionitrile, N,N-dimethylformamide, and mixtures of these solvents. Each of these solvents can be used alone or in combination.
- the reaction can be performed in the presence of a polymerization inhibitor if desired.
- polymerization inhibitors include, but are not limited to, hydroquinone, hydroquinone monomethyl ether, phenothiazine, 2,6-di-tert-butyl-p-cresol, thiourea, urea, and N-phenyl-N′-isopropyl-p-phenyldiamine.
- the amount of the polymerization inhibitor is from about 100 to about 100000 ppm and preferably from about 500 to about 5000 ppm relative to the amount of the target compound.
- the piperazine-containing liquid crystalline compound represented by general formula (1) is obtained according to a conventional purification procedure such as extraction and recrystallization.
- the piperazine-containing liquid crystalline compound represented by general formula (1) can be easily obtained.
- the resulting compound has a thermotropically stable liquid crystal phase and exhibits a smectic B phase as a liquid crystal phase.
- the piperazine-containing liquid crystalline compound represented by general formula (1) has an unsaturated bond and can yield a polymeric charge transport material as a result of a polymerization reaction.
- FIG. 1 is a schematic diagram of a charge transport device as an embodiment of the present invention.
- the charge transport device of the present invention is prepared in the following manner. Initially, electrodes 2 a and 2 b made of a transparent electrode such as ITO are formed on surfaces of a pair of glass substrates 1 a and 1 b , respectively. The pair of substrates carrying the electrodes are bonded with each other using an adhesive in such a manner that cell distance is held constant using a spacer 4 to thereby form a cell.
- a transparent electrode such as ITO
- the above liquid crystalline compound exhibiting a smectic B phase as a liquid crystal phase is injected into the cell to form a liquid crystal layer 3 between the electrodes, and a voltage application means 5 is connected to the electrodes 2 a and 2 b .
- the voltage application means 5 serves to apply a voltage to the liquid crystalline compound in a smectic B liquid crystal phase in the liquid crystal layer 3 .
- a voltage is applied to the liquid crystalline compound in a smectic B liquid crystal phase in the liquid crystal layer 3 by a charge transport means comprising the voltage application means 5 , a temperature control means (not shown) for the liquid crystal phase, and other components.
- the charge transport method and the charge transport device of the present invention transport charges by applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, which liquid crystalline compound exhibits the smectic B phase as a liquid crystal phase.
- a liquid crystalline compound having a strongly basic moiety in its skeleton liquid crystal molecules each having the strongly basic moiety, namely, a moiety with high electron density are overlapped in the smectic B liquid crystal phase where molecules densely overlap with each other.
- the method can transport charges at a high current density on the order of microamperes per square centimeter without the wide spreading of a conjugated system, in contrast to conventional charge transport materials.
- the charge transport method and the charge transport device can be advantageously used as charge transport methods and charge transport devices in optical sensors, electroluminescent devices, photoconductors, spatial light modulators, thin film transistors, and other sensors, utilizing their charge transporting capabilities.
- the charge transport method according to the second invention of the present invention comprises the step of applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase.
- This charge transport method of the present invention has been accomplished based on the following findings. Specifically, when a liquid crystalline compound exhibiting a smectic phase as a liquid crystal phase is allowed to undergo phase transition into a solid state while the smectic phase is maintained, the resulting liquid crystalline compound includes basic moieties overlapped with a higher density even in a solid state. The resulting liquid crystalline compound can exhibit higher charge transport capability with a high current density only by the application of a voltage without photo-induced excitation.
- Liquid crystals for use in the charge transport method of the present invention are not specifically limited, as long as they are liquid crystalline compounds exhibiting a smectic phase, and include known liquid crystalline compounds. Among them, those exhibiting smectic B phase as a liquid crystal phase are preferred.
- the liquid crystals may also be polymeric liquid crystalline compounds exhibiting a smectic phase.
- liquid crystalline compounds exhibiting a smectic phase for use in the charge transport method of the present invention, those having a strongly basic moiety in their skeleton are preferred.
- liquid crystalline compounds are liquid crystalline compounds represented by following general formula (6): R 3 —A—B—R 4 (6)
- R 3 and R 4 are as follows:
- B is a basic ring and includes, for example, the followings:
- those having an unsaturated bond can also be used as polymeric charge transport materials as a result of a polymerization reaction.
- a voltage can be applied to the liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase induced by temperature depression, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase.
- Such solid states include, for example, a crystal phase, glassy state, and amorphous solid state.
- FIG. 2 is a schematic diagram of a charge transport device as another embodiment of the present invention.
- the charge transport device of the present invention is prepared in the following manner. Initially, electrodes 2 a and 2 b made of a transparent electrode such as ITO are formed on surfaces of a pair of glass substrate 1 a and 1 b , respectively. The pair of substrates carrying the electrodes are bonded with each other using an adhesive in such a manner that a cell distance is held constant using a spacer 4 to thereby form a cell.
- a transparent electrode such as ITO
- the above liquid crystalline compound exhibiting a smectic phase as a liquid crystal phase is injected into the cell to form a liquid crystal layer 13 between the electrodes, and a voltage application means 5 is connected to the electrodes 2 a and 2 b .
- the voltage application means 5 serves to apply a voltage to the liquid crystalline compound in a solid state formed as a result of phase transition from the smectic phase in the liquid crystal layer 13 .
- a voltage is applied to the liquid crystalline compound in the liquid crystal layer 13 in a solid state formed as a result of phase transition from the smectic phase by a charge transport means comprising the voltage application means 5 , a temperature control means (not shown) for the liquid crystal phase, and other components.
- the charge transport method and the charge transport device of the present invention transport charges by applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase induced by temperature depression, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase.
- the liquid crystalline compound undergoes phase transition to a solid state while keeping the alignment of the smectic phase.
- liquid crystal molecules each having the strongly basic moiety are overlapped with a high density.
- the method and device can transport charges at a high current density at least on the order of microamperes per square centimeter, and preferably on the order of milliamperes per square centimeter, in contrast to conventional charge transport materials. Accordingly, the charge transport method and the charge transport device can be advantageously used as charge transport methods and charge transport devices in optical sensors, electroluminescent devices, photoconductors, spatial light modulators, thin film transistors, and other sensors, utilizing their charge transporting capabilities.
- the resulting solution was poured into 300 mL of ice water, was extracted with two portions of 300 mL of diethyl ether, was washed with 300 mL of distilled water, and was then dehydrated over anhydrous sodium sulfate overnight. After filtration, the solution was diluted with hexane and was separated into soluble matters and insoluble matters. The hexane-soluble matters were then recrystallized from ether and hexane (1:3) and thereby yielded 1-[4-(9-decenyloxy)phenyl]piperazine.
- a total of 0.2 g of a polymerization inhibitor (phenothiazine) was dissolved in N,N-dimethylformamide.
- a polymerization inhibitor phenothiazine
- To the resulting solution were added and dissolved 0.62 g (0.0032 mol) of octyl bromide, 2.5 g (0.016 mol) of 1,8-diazabicyclo[5.4.0]-7-undecene (DBU), and 1 g (0.0032 mol) of the above-prepared 1-[4-(9-decenyloxy)phenyl]piperazine, followed by a reaction at 60° C. in an atmosphere of nitrogen gas for 48 hours with stirring.
- DBU 1,8-diazabicyclo[5.4.0]-7-undecene
- the solution was poured into ice water, extracted with two portions of 300 mL of diethyl ether, washed with 300 mL of distilled water and dehydrated over anhydrous sodium sulfate overnight. After filtration, the solution was diluted with hexane and separated into soluble matters and insoluble matter. The hexane-soluble matter was then recrystallized from ether and hexane (1:3) and thereby yielded the target compound, 1-[4-(9-decenyloxy)phenyl]-4-octylpiperazine.
- phase transition temperatures of the above compound were determined, and the results were as follows.
- an X-ray chart of the 1-[4-(9-decenyloxy)phenyl]-4-octylpiperazine is shown in FIG. 3 . wherein Cryst. is a crystal, SmB is smectic B phase, and Iso. is isotropic liquid.
- the target compound was synthetically prepared in the same manner as in Reference Example 1, except that 0.71 g (0.0032 mol) of decyl bromide was used instead of octyl bromide.
- the prepared compound was subjected to analyses by 1 H-NMR, MASS, and IR and was identified with 1-[4-(9-decenyloxy)phenyl]-4-decylpiperazine.
- phase transition temperatures of the above compound were determined, and the results were as follows.
- the target compound was synthetically prepared in the same manner as in Reference Example 1, except that 0.75 g (0.0032 mol) of undecyl bromide was used instead of octyl bromide.
- the prepared compound was subjected to analyses by 1 H-NMR, MASS, and IR and was identified with 1-[4-(9-decenyloxy)phenyl]-4-undecylpiperazine.
- phase transition temperatures of the above compound were determined, and the results were as follows.
- the target compound was synthetically prepared in the same manner as in Reference Example 1, except that 0.80 g (0.0032 mol) of dodecyl bromide was used instead of octyl bromide.
- the prepared compound was subjected to analyses by 1 H-NMR, MASS, and IR and was identified with 1-[4-(9-decenyloxy)phenyl]-4-dodecylpiperazine.
- phase transition temperatures of the above compound were determined, and the results were as follows.
- ITO films were formed on two glass substrates by vacuum film formation, respectively, and the two glass substrates were bonded with each other with a gap (about 15 ⁇ m) using a spacer particle and thereby yielded a cell.
- FIGS. 4 to 7 show that charge transportation according to the present invention is not based on photoelectric effect but on the activities of the compound itself, and that higher charge transporting effects are obtained in the smectic B phase.
- a cell was prepared in the same manner as in Example 1, and 1-[4-(9-decenyloxy)phenyl]-4-decylpiperazine obtained in Reference Example 4 was injected into the cell at 110° C. The compound in the cell was then cooled to 55° C. and thereby yielded a solid having orientation (alignment) of the smectic B phase.
- a voltage is applied to a smectic B liquid crystal or a solid formed as a result of phase transition from a smectic phase.
- the methods and devices have very excellent advantages in that they can transport charges with a current density on the order of microamperes per square centimeter to milliamperes per square centimeter.
Landscapes
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Liquid Crystal Substances (AREA)
- Electroluminescent Light Sources (AREA)
Abstract
An electric charge transport method with a high current density and excellent charge transporting capability is provided. Specifically, the charge transport method includes applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, which liquid crystalline compound exhibits a smectic B phase as a liquid crystal phase, or applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase.
Description
The present invention relates to novel electrical charge transport methods and charge transport devices using liquid crystalline compounds.
Investigations on organic electroluminescent devices using organic materials as electron hole transport materials and electric charge (hereafter simply referred to as charge) transport materials constituting electroluminescent devices have been actively pursued in recent years.
As conventional charge transport materials, anthracene derivatives, anthraquinone derivatives, imidazole derivatives, styryl derivatives, hydrazine derivatives, triphenylamine compounds, poly(N-vinylcarbazole), oxadiazole, and other compounds are known.
Liquid crystalline compounds are applied, as display materials, to various apparatus such as clocks, electronic desk-top calculators, television sets, personal computers, and cellular phones. Liquid crystalline substances are categorized as thermotropic liquid crystals and lyotropic liquid crystals based on their phase transition means. From the viewpoint of molecular alignment, these liquid crystals are categorized into three groups, namely smectic liquid crystals, nematic liquid crystals, and cholesteric liquid crystals. The liquid crystals have a synonym of anisotropic liquids and are optically anisotropic as in optically uniaxial crystals. Orthoscopic observation is observation performed between regular crossed nicols and is useful for the identification of the types of liquid crystals or for the determination of transition temperatures of liquid crystal phases. The individual liquid crystals show characteristic birefringent optical patterns upon the orthoscopic observation, and the smectic crystals are further categorized as A, B, C, D, E, F, G and other smectic phases.
Hanna et al. have found liquid crystalline compounds having a smectic liquid crystal phase are capable of transporting charges and have proposed charge transport materials using these liquid crystalline compounds. They have proposed, for example, a liquid crystalline charge transport material exhibiting smectic liquid crystallinity and having a reduction potential with respect to a standard calomel electrode (SCE) in the range of from −0.3 to −0.6 (V vs. SCE) (Japanese Patent Laid open No. 09-316442), a liquid crystalline charge transport material comprising a liquid crystalline compound exhibiting a smectic phase having self-orientation properties and a predetermined amount of fullerene C70 capable of sensitizing (Japanese Patent Laid open No. 11-162648), a high polymer membrane comprising a liquid crystalline charge transport material dispersed therein in which a liquid crystalline compound exhibiting a smectic phase is dispersed in an organic polymeric matrix (Japanese Patent Laid open No. 11-172118), a liquid crystalline charge transport material comprising a mixture containing a smectic liquid crystalline compound (Japanese Patent Laid open No. 11-199871), a liquid crystalline charge transport material having smectic liquid crystallinity and an electron mobility or electron hole mobility of not less than 1×10−5 cm2/v.s (Japanese Patent Laid open No. 10-312711), and a liquid crystalline charge transport material comprising a smectic liquid crystalline compound having, in one molecule, a functional group capable of forming a new intermolecular or intramolecular bond and a functional group capable of transporting holes and/or electron charges (Japanese Unexamined Patent Application Publication No. 11-209761).
The above-proposed smectic liquid crystalline compounds are smectic liquid crystalline compounds having 6 π-electron aromatic rings such as benzene ring, pyridine ring, pyrimidine ring, pyridazine ring, pyrazine ring, tropolone ring, and compounds having 10 π-electron aromatic rings such as naphthalene ring, azulene ring, benzofuran ring, indole ring, indazole ring, benzothiazole ring, benzoxazole ring, benzimidazole ring, quinoline ring, isoquinoline ring, quinazoline ring, quinoxaline ring, and compounds having 14 π-electron aromatic rings such as phenanthrene ring, anthracene ring, and others. These compounds are used for charge transporting in a smectic A liquid crystal phase. Such charge transporting with the aid of smectic A phase is charge transporting using spread of a conjugated system in the molecule. Accordingly, none of these compounds can exhibit excellent charge transporting capability unless they are excited by, for example, light. In addition, they have a low current density, at most on the order of nanoamperes per square centimeter.
The present invention has been accomplished in view of these conventional technologies, and an object of the present invention is to provide a method and device for transporting an electric charge which exhibit a high current density and have excellent charge transporting capability by applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, which liquid crystalline compound exhibits a smectic B phase as a liquid crystal phase.
Another object of the present invention is to provide a charge transport method and a charge transport device which exhibit a high current density and have excellent charge transporting capability by applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase induced by temperature depression, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase.
Specifically, the first invention of the present invention is a charge transport method comprising the step of applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, which liquid crystalline compound exhibits the smectic B phase as a liquid crystal phase.
The second invention of the present invention is a charge transport method comprising the step of applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase.
The liquid crystalline compounds are preferably smectic liquid crystalline compounds each having a strongly basic moiety in their skeleton.
The third invention of the present invention is a charge transport device comprising a pair of substrates each having an electrode; a liquid crystal layer sandwiched between the substrates and comprising a liquid crystalline compound exhibiting a smectic B phase as a liquid crystal phase; and means for applying a voltage to the liquid crystalline compound in a smectic B liquid crystal phase to thereby transport charges through the liquid crystal layer.
In addition, a fourth invention of the present invention is a charge transport device comprising a pair of substrates each having an electrode; a liquid crystal layer sandwiched between the substrates and comprising a liquid crystalline compound exhibiting a smectic phase as a liquid crystal phase; and means for applying a voltage to the liquid crystalline compound in a solid state formed as a result of phase transition from the smectic phase to thereby transport charges through the liquid crystal layer.
In the figures, 1 a and 1 b are glass substrates, 2 a and 2 b are electrodes, 4 is a spacer, 3 and 13 are liquid crystal layers, and 5 is a voltage application means, respectively.
The present invention will be illustrated in further detail below.
The charge transport method according to the first invention of the present invention comprises the step of applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, which liquid crystalline compound exhibits the smectic B phase as a liquid crystal phase.
The charge transport method of the present invention has been accomplished based on the following novel findings. Specifically, when a voltage is applied to a liquid crystalline compound in a smectic B liquid crystal phase where the liquid crystalline compound exhibits the smectic B phase as a liquid crystal phase, the liquid crystalline compound shows higher charge transporting capability only by the application of a voltage without photo-induced excitation. Particularly, when a liquid crystalline compound having a strongly basic moiety in its skeleton is used, liquid crystal molecules each having the strongly basic moiety, namely a moiety with high electron density are overlapped in the smectic B liquid crystal phase where molecules overlap densely. By this configuration, the method can transport charges at a high current density at least on the order of microamperes per square centimeter without the wide spreading of a conjugated system as in a smectic A phase, in contrast to conventional charge transport materials.
Liquid crystals for use in the charge transport method of the present invention are not specifically limited as long as they are liquid crystalline compounds exhibiting smectic B phase as a liquid crystal phase, and known compounds can be used. Such liquid crystalline compounds exhibiting a smectic B phase can be whichever liquid crystalline compound exhibits a smectic B phase alone as a liquid crystal phase or those exhibiting other smectic phase(s) in addition to the smectic B phase. For example, the liquid crystalline compounds may be those exhibiting A phase and B phase, those exhibiting A phase, B phase, and C phase, and any other liquid crystalline compounds exhibiting smectic B phase. The liquid crystalline compounds may also be polymeric liquid crystalline compounds exhibiting smectic B phase.
Among the liquid crystalline compounds having a smectic B phase for use in the charge transport method of the present invention, preference is given to those having a strongly basic moiety in their skeletons, of which those having a monocyclic heterocycle in its skeleton are especially preferred.
Preferred monocyclic heterocycles include, for example, piperidine, piperazine, pyridine, pyridazine, pyrimidine, and pyrazine. Among them, liquid crystalline compounds having piperazine in their skeletons are especially preferred.
More specifically, piperazine-containing liquid crystalline compounds represented by the following general formula (1) are more preferred.
In general formula (1) representing the piperazine-containing liquid crystalline compounds, R1 is a hydrogen atom or a methyl group.
R2 is a straight- or branched-chain alkyl group containing from 1 to 22 carbon atoms, such as methyl group, ethyl group, propyl group, butyl group, octyl group, decyl group, dodecyl group, and octadecyl group. Among them, those containing from 8 to 14 carbon atoms are especially preferred.
A is an alkylene group, and preference is given to those containing from 6 to 10 carbon atoms. Examples of such alkylene groups are methylene groups, ethylene groups, trimethylene groups, tetramethylene groups, pentamethylenes groups, ethylethylene groups, propylene groups, butylene groups, hexylene groups, octadecylene groups, nonylene groups, decylene groups, and dodecylene groups.
Preferred examples of the piperazine-containing liquid crystalline compounds represented by general formula (1) include:
- 1-[4-(6-heptenyloxy)phenyl]-4-octylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-nonylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-decylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-undecylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-dodecylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-tridecylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-tetradecylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-pentadecylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-hexadecylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-heptadecylpiperazine,
- 1-[4-(6-heptenyloxy)phenyl]-4-octadecylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-octylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-nonylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-decylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-undecylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-dodecylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-tridecylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-tetradecylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-pentadecylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-hexadecylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-heptadecylpiperazine,
- 1-[4-(7-octenyloxy)phenyl]-4-octadecylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-octylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-nonylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-decylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-undecylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-dodecylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-tridecylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-tetradecylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-pentadecylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-hexadecylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-heptadecylpiperazine,
- 1-[4-(8-nonenyloxy)phenyl]-4-octadecylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-octylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-nonylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-decylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-undecylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-dodecylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-tridecylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-tetradecylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-pentadecylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-hexadecylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-heptadecylpiperazine,
- 1-[4-(9-decenyloxy)phenyl]-4-octadecylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-octylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-nonylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-decylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-undecylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-dodecylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-tridecylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-tetradecylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-pentadecylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-hexadecylpiperazine,
- 1-[4-(10-undecenyloxy)phenyl]-4-heptadecylpiperazine, and
- 1-[4-(10-undecenyloxy)phenyl]-4-octadecylpiperazine.
The piperazine-containing liquid crystalline compounds represented by general formula (1) can be prepared, for example, according to the following reaction formulae (1) and (2):
Reaction Formula (1)
Reaction Formula (2)
wherein R1 and R2 have the same meanings as defined above; X is a halogen atom such as a chlorine atom and fluorine atom; and M is an alkali metal such as potassium and sodium.
Reaction Formula (1)
Reaction Formula (2)
wherein R1 and R2 have the same meanings as defined above; X is a halogen atom such as a chlorine atom and fluorine atom; and M is an alkali metal such as potassium and sodium.
Specifically, according to reaction formula (1), a piperazine derivative represented by general formula (4) can be easily obtained by reacting a halide represented by general formula (2) with an alcoholate represented by general formula (3) in an organic solvent.
The molar ratio of the alcoholate of general formula (3) to the halide of general formula (2) is generally from 1 to 4, and preferably from 1 to 2. The reaction temperature is generally from 0° C. to 100° C. and preferably from 10° C. to 40° C., and the reaction time is generally from 1 to 50 hours and preferably from 10 to 30 hours.
Reaction solvents are not specifically limited, as long as they can dissolve the halide and alcoholate and are inert, and include, for example, toluene, xylenes, benzene, and other aromatic hydrocarbons; 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1,1,2-tetrachloroethane, 1,1,2,2-tetrachloroethane, and other haloalkanes; and N,N-dimethylformamide. Each of these solvents can be used alone or in combination. After the completion of the reaction, the piperazine derivative represented by general formula (4) is obtained according to a conventional purification procedure such as extraction and recrystallization.
Next, according to the reaction shown in reaction formula (2), a piperazine-containing liquid crystalline compound represented by general formula (1) can be easily prepared by reacting the piperidine derivative represented by general formula (4) with an alkyl halide represented by general formula (5) in an organic solvent in the presence of a base.
The molar ratio of the alkyl halide represented by general formula (5) to the piperidine derivative represented by general formula (4) is generally from 1 to 4 and preferably from 1 to 2. The reaction temperature is generally from 0° C. to 100° C. and preferably from 20° C. to 80° C., and the reaction time is generally from 1 to 60 hours and preferably from 24 to 50 hours.
Examples of the base include, but are not limited to, sodium hydroxide, sodium carbonate, sodium hydrogencarbonate, potassium hydroxide, potassium carbonate, potassium hydrogencarbonate, calcium hydroxide, calcium carbonate, and other inorganic bases; trimethylamine, N,N-dimethylcyclohexylamine, N,N-diethylcyclohexylamine, N,N-dimethylbenzylamine, N,N′-dimethylpiperazine, N,N-dimethylaniline, N,N-diethylaniline, N,N,N′, N′-tetramethyl-1,3-propanediamine, pyridine, α-picoline, β-picoline, γ-picoline, 4-ethylmorpholine, triethylenediamine, 1,3-diazabicyclo[5,4,0]undecene, 1,8-diazabicyclo[5,4,0]-7-undecene, N-ethylpiperidine, quinoline, isoquinoline, N,N-dimethylpiperazine, N,N-diethylpiperazine, quinaldine, 2-ethylpyridine, 4-ethylpyridine, 3,5-lutidine, 2,6-lutidine, 4-methylmorpholine, 2,4,6-collidine, and other organic bases; and ion exchange resins each having pyridyl group or methylaminobenzyl group.
The amount of the base has only to be an amount sufficient to capture a hydrogen halide formed as by-product and is generally from 1 to 6 times, preferably from 1 to 3 times, and more preferably from 1.1 to 2 times the stoichiometric amount of the by-produced hydrogen halide.
Reaction solvents for use herein are not specifically limited, as long as they can dissolve the alkyl halide and the piperidine derivative represented by general formula (4) and are inert, and include, for example, dioxane, tetrahydrofuran, dibutyl ether, and other ethers; acetonitrile, propionitrile, N,N-dimethylformamide, and mixtures of these solvents. Each of these solvents can be used alone or in combination.
The reaction can be performed in the presence of a polymerization inhibitor if desired. Such polymerization inhibitors include, but are not limited to, hydroquinone, hydroquinone monomethyl ether, phenothiazine, 2,6-di-tert-butyl-p-cresol, thiourea, urea, and N-phenyl-N′-isopropyl-p-phenyldiamine. The amount of the polymerization inhibitor is from about 100 to about 100000 ppm and preferably from about 500 to about 5000 ppm relative to the amount of the target compound.
After completion of the reaction, the piperazine-containing liquid crystalline compound represented by general formula (1) is obtained according to a conventional purification procedure such as extraction and recrystallization.
By the above process, the piperazine-containing liquid crystalline compound represented by general formula (1) can be easily obtained. The resulting compound has a thermotropically stable liquid crystal phase and exhibits a smectic B phase as a liquid crystal phase.
The piperazine-containing liquid crystalline compound represented by general formula (1) has an unsaturated bond and can yield a polymeric charge transport material as a result of a polymerization reaction.
The charge transport method and the charge transport device of the present invention transport charges by applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, which liquid crystalline compound exhibits the smectic B phase as a liquid crystal phase. Particularly, when a liquid crystalline compound having a strongly basic moiety in its skeleton is used, liquid crystal molecules each having the strongly basic moiety, namely, a moiety with high electron density are overlapped in the smectic B liquid crystal phase where molecules densely overlap with each other. By this configuration, the method can transport charges at a high current density on the order of microamperes per square centimeter without the wide spreading of a conjugated system, in contrast to conventional charge transport materials. Accordingly, the charge transport method and the charge transport device can be advantageously used as charge transport methods and charge transport devices in optical sensors, electroluminescent devices, photoconductors, spatial light modulators, thin film transistors, and other sensors, utilizing their charge transporting capabilities.
The charge transport method according to the second invention of the present invention comprises the step of applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase.
This charge transport method of the present invention has been accomplished based on the following findings. Specifically, when a liquid crystalline compound exhibiting a smectic phase as a liquid crystal phase is allowed to undergo phase transition into a solid state while the smectic phase is maintained, the resulting liquid crystalline compound includes basic moieties overlapped with a higher density even in a solid state. The resulting liquid crystalline compound can exhibit higher charge transport capability with a high current density only by the application of a voltage without photo-induced excitation.
Liquid crystals for use in the charge transport method of the present invention are not specifically limited, as long as they are liquid crystalline compounds exhibiting a smectic phase, and include known liquid crystalline compounds. Among them, those exhibiting smectic B phase as a liquid crystal phase are preferred. The liquid crystals may also be polymeric liquid crystalline compounds exhibiting a smectic phase.
Among such liquid crystalline compounds exhibiting a smectic phase for use in the charge transport method of the present invention, those having a strongly basic moiety in their skeleton are preferred.
More specifically, examples of such liquid crystalline compounds are liquid crystalline compounds represented by following general formula (6):
R3—A—B—R4 (6)
R3—A—B—R4 (6)
Among the aforementioned liquid crystalline compounds, those having an unsaturated bond can also be used as polymeric charge transport materials as a result of a polymerization reaction.
In charge transportation, a voltage can be applied to the liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase induced by temperature depression, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase. Such solid states include, for example, a crystal phase, glassy state, and amorphous solid state.
The charge transport method and the charge transport device of the present invention transport charges by applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase induced by temperature depression, which liquid crystalline compound exhibits the smectic phase as a liquid crystal phase. In this procedure, the liquid crystalline compound undergoes phase transition to a solid state while keeping the alignment of the smectic phase. Particularly, when a liquid crystalline compound having a strongly basic moiety in its skeleton is used, liquid crystal molecules each having the strongly basic moiety are overlapped with a high density. By this configuration, the method and device can transport charges at a high current density at least on the order of microamperes per square centimeter, and preferably on the order of milliamperes per square centimeter, in contrast to conventional charge transport materials. Accordingly, the charge transport method and the charge transport device can be advantageously used as charge transport methods and charge transport devices in optical sensors, electroluminescent devices, photoconductors, spatial light modulators, thin film transistors, and other sensors, utilizing their charge transporting capabilities.
The present invention will be illustrated in further detail with reference to several examples below, which are not intended to limit the scope of the invention.
Preparation of 1-[4-(9-decenyloxy)phenyl]-4-octylpiperazine
In 50 mL of methanol was dissolved 0.72 g (0.017 mol) of sodium hydroxide (94%) at room temperature. After cooling, the solution was treated with 3 g (0.017 mol) of 1-(4-hydroxyphenyl)piperazine, and excess methanol was removed under reduced pressure. A total of 3.7 g (0.017 mol) of 10-bromo-1-decene was added to 50 mL of N,N-dimethylformamide and was stirred at room temperature for 24 hours. The resulting solution was poured into 300 mL of ice water, was extracted with two portions of 300 mL of diethyl ether, was washed with 300 mL of distilled water, and was then dehydrated over anhydrous sodium sulfate overnight. After filtration, the solution was diluted with hexane and was separated into soluble matters and insoluble matters. The hexane-soluble matters were then recrystallized from ether and hexane (1:3) and thereby yielded 1-[4-(9-decenyloxy)phenyl]piperazine.
A total of 0.2 g of a polymerization inhibitor (phenothiazine) was dissolved in N,N-dimethylformamide. To the resulting solution were added and dissolved 0.62 g (0.0032 mol) of octyl bromide, 2.5 g (0.016 mol) of 1,8-diazabicyclo[5.4.0]-7-undecene (DBU), and 1 g (0.0032 mol) of the above-prepared 1-[4-(9-decenyloxy)phenyl]piperazine, followed by a reaction at 60° C. in an atmosphere of nitrogen gas for 48 hours with stirring. After completion of the reaction, the solution was poured into ice water, extracted with two portions of 300 mL of diethyl ether, washed with 300 mL of distilled water and dehydrated over anhydrous sodium sulfate overnight. After filtration, the solution was diluted with hexane and separated into soluble matters and insoluble matter. The hexane-soluble matter was then recrystallized from ether and hexane (1:3) and thereby yielded the target compound, 1-[4-(9-decenyloxy)phenyl]-4-octylpiperazine.
Identification Data
1H-NMR (ppm; CDCl3) δ
-
- 0.8 (t, 3H), 1.2-2.5 (m, 3OH), 2.5-3.2 (dt, 8H), 3.8-4.0 (t, 2H), 4.8-5.2 (m, 2H), 5.5-6.2 (m, 1H), 6.7-7.1 (d, 4H)
IR; ν (KBr) cm−1;
-
- 2800-3000, 1517, 1251, 1031
MASS (FAB) m/z; 428 (M+1)
The phase transition temperatures of the above compound were determined, and the results were as follows. In addition, an X-ray chart of the 1-[4-(9-decenyloxy)phenyl]-4-octylpiperazine is shown in FIG. 3.
wherein Cryst. is a crystal, SmB is smectic B phase, and Iso. is isotropic liquid.
wherein Cryst. is a crystal, SmB is smectic B phase, and Iso. is isotropic liquid.
Preparation of 1-[4-(9-decenyloxy)phenyl]-4-decylpiperazine
The target compound was synthetically prepared in the same manner as in Reference Example 1, except that 0.71 g (0.0032 mol) of decyl bromide was used instead of octyl bromide. The prepared compound was subjected to analyses by 1H-NMR, MASS, and IR and was identified with 1-[4-(9-decenyloxy)phenyl]-4-decylpiperazine.
The phase transition temperatures of the above compound were determined, and the results were as follows.
Preparation of 1-[4-(9-decenyloxy)phenyl]-4-undecylpiperazine
The target compound was synthetically prepared in the same manner as in Reference Example 1, except that 0.75 g (0.0032 mol) of undecyl bromide was used instead of octyl bromide. The prepared compound was subjected to analyses by 1H-NMR, MASS, and IR and was identified with 1-[4-(9-decenyloxy)phenyl]-4-undecylpiperazine.
The phase transition temperatures of the above compound were determined, and the results were as follows.
Preparation of 1-[4-(9-decenyloxy)phenyl]-4-dodecylpiperazine
The target compound was synthetically prepared in the same manner as in Reference Example 1, except that 0.80 g (0.0032 mol) of dodecyl bromide was used instead of octyl bromide. The prepared compound was subjected to analyses by 1H-NMR, MASS, and IR and was identified with 1-[4-(9-decenyloxy)phenyl]-4-dodecylpiperazine.
The phase transition temperatures of the above compound were determined, and the results were as follows.
ITO films were formed on two glass substrates by vacuum film formation, respectively, and the two glass substrates were bonded with each other with a gap (about 15 μm) using a spacer particle and thereby yielded a cell.
A total of 20 mg of 1-[4-(9-decenyloxy)phenyl]-4-decylpiperazine prepared in Reference Example 2 was injected into the cell at 110° C.
Next, dark currents at 0 V, 5 V, 10 V, 15 V, and 20 V, and changes in current with voltage in the smectic B phase (70° C.) were determined. The results are shown in FIGS. 4 and 5 .
Separately, dark currents at 0 V, 5 V, 10 V, 15 V, and 20 V, and changes in current with voltage in the isotropic liquid phase (75° C.) were determined. The results are shown in FIGS. 6 and 7 . Current densities were determined based on FIGS. 5 and 7 , and the results are shown in Table 1.
TABLE 1 | ||
Applied | Current density (μA/cm3) |
Voltage (V) | SmB phase (70° C.) | Isotropic liquid (75° C.) |
5 | 93 | 38 |
10 | 240 | 110 |
15 | 360 | 210 |
20 | 420 | 300 |
The results in FIGS. 4 to 7 show that charge transportation according to the present invention is not based on photoelectric effect but on the activities of the compound itself, and that higher charge transporting effects are obtained in the smectic B phase.
A cell was prepared in the same manner as in Example 1, and 1-[4-(9-decenyloxy)phenyl]-4-decylpiperazine obtained in Reference Example 4 was injected into the cell at 110° C. The compound in the cell was then cooled to 55° C. and thereby yielded a solid having orientation (alignment) of the smectic B phase.
Next, current densities of the resulting solid were determined in the same manner as in Example 1. As a result, current density at 5 V was 103 milliamperes per square centimeter (mA/cm2).
According to the charge transport methods and devices of the present invention as described above, a voltage is applied to a smectic B liquid crystal or a solid formed as a result of phase transition from a smectic phase. By this configuration, the methods and devices have very excellent advantages in that they can transport charges with a current density on the order of microamperes per square centimeter to milliamperes per square centimeter.
Claims (9)
1. An electric charge transport method comprising the step of applying a voltage to a liquid crystalline compound in a smectic B liquid crystal phase, the liquid crystalline compound exhibiting a smectic B phase as a liquid crystal phase, wherein the liquid crystalline compound is a liquid crystalline compound having a strongly basic moiety in its skeleton.
2. The electric charge transport method according to claim 1 , wherein the strongly basic moiety is a monocyclic heterocycle.
3. The electric charge transport method according to claim 2 , wherein the monocyclic heterocycle is selected from piperidine, piperazine, pyridine, pyridazine, pyrimidine, and pyrazine.
4. The electric charge transport method according to claim 2 or 3 , wherein the monocyclic heterocycle is piperazine.
5. The electric charge transport method according to claim 1 , wherein the liquid crystalline compound is a piperazine-containing liquid crystalline compound represented by following general formula (1):
wherein R1 is a hydrogen atom or a methyl group; R2 is a straight- or branched-chain alkyl group containing from 1 to 22 carbon atoms; and A is an alkylene group.
6. An electric charge transport method comprising the step of applying a voltage to a liquid crystalline compound in a solid state formed as a result of phase transition from a smectic phase, the liquid crystalline compound exhibiting the smectic phase as a liquid crystal phase.
7. The electric charge transport method according to claim 6 , wherein the liquid crystalline compound is a smectic liquid crystalline compound having a strongly basic moiety in its skeleton.
8. An electric charge transport device comprising a pair of substrates each having an electrode; a liquid crystal layer sandwiched between the substrates and comprising a liquid crystalline compound having a strongly basic moiety in its skeleton exhibiting smectic B phase as a liquid crystal phase; and means for applying a voltage to the liquid crystalline compound in a smectic B liquid crystal phase to thereby transport charges through the liquid crystal layer.
9. An electric charge transport device comprising a pair of substrates each having an electrode; a liquid crystal layer sandwiched between the substrates, the layer comprising a liquid crystalline compound exhibiting a smectic phase as a liquid crystal phase; and means for applying a voltage to the liquid crystalline compound in a solid state formed as a result of phase transition from the smectic phase to thereby transport charges through the liquid crystal layer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000168057A JP4396907B2 (en) | 2000-06-05 | 2000-06-05 | Charge transport method |
JP2000-168057 | 2000-06-05 | ||
JP0104621 | 2001-05-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030160211A1 US20030160211A1 (en) | 2003-08-28 |
US6838129B2 true US6838129B2 (en) | 2005-01-04 |
Family
ID=18671121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/296,226 Expired - Fee Related US6838129B2 (en) | 2000-06-05 | 2001-05-31 | Method and device for transporting an electrical charge |
Country Status (2)
Country | Link |
---|---|
US (1) | US6838129B2 (en) |
JP (1) | JP4396907B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090250676A1 (en) * | 2005-07-14 | 2009-10-08 | Yamanashi University | Liquid crystalline organic semiconductor material, and semiconductor element or information recording medium using the same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4574549B2 (en) * | 2003-03-24 | 2010-11-04 | 日本化学工業株式会社 | Benzene derivative having a long linear conjugated structure, its production method and liquid crystalline material |
JP5353852B2 (en) * | 2010-09-28 | 2013-11-27 | コニカミノルタ株式会社 | Surface light emitter and method for manufacturing surface light emitter |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11260428A (en) | 1998-03-11 | 1999-09-24 | Toshiba Corp | Photochemical cell |
JP2000068052A (en) * | 1998-08-26 | 2000-03-03 | Dainippon Printing Co Ltd | Liquid crystal element drive method |
-
2000
- 2000-06-05 JP JP2000168057A patent/JP4396907B2/en not_active Expired - Fee Related
-
2001
- 2001-05-31 US US10/296,226 patent/US6838129B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11260428A (en) | 1998-03-11 | 1999-09-24 | Toshiba Corp | Photochemical cell |
JP2000068052A (en) * | 1998-08-26 | 2000-03-03 | Dainippon Printing Co Ltd | Liquid crystal element drive method |
Non-Patent Citations (1)
Title |
---|
English translation by computer for JP 2000-68052, http://www6.ipdl.jpo.go.jp/Tokujitu/PAJdetail.ipdl?N0000=80&N0120=01&N2001=2&N3001=2000-068052. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090250676A1 (en) * | 2005-07-14 | 2009-10-08 | Yamanashi University | Liquid crystalline organic semiconductor material, and semiconductor element or information recording medium using the same |
US8039832B2 (en) * | 2005-07-14 | 2011-10-18 | Yamanashi University | Liquid crystalline organic semiconductor material, and semiconductor element or information recording medium using the same |
Also Published As
Publication number | Publication date |
---|---|
US20030160211A1 (en) | 2003-08-28 |
JP4396907B2 (en) | 2010-01-13 |
JP2001351786A (en) | 2001-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0972817B1 (en) | Ferroelectric charge-transport liquid crystal material | |
JP2001081466A (en) | Active matrix display having high contrast value | |
JP4271469B2 (en) | Charge transport method and charge transport device using liquid crystal molecules having a long linear conjugated structure | |
US6838129B2 (en) | Method and device for transporting an electrical charge | |
Seki et al. | Ferroelectric Liquid-Crystalline Binary Mixtures Based on Achiral and Chiral Trifluoromethylphenylterthiophenes | |
US7615262B2 (en) | Liquid crystal material, method for producing liquid crystal material and liquid crystal device | |
US8970937B2 (en) | Electrochromic materials and electrochromic devices using the same | |
EP0878460A1 (en) | Racemic compound and anti-ferroelectric liquid crystal composition containing the compound | |
US7482494B2 (en) | Benzene derivative having long, linear conjugated structure, process for producing benzene derivative, and charge-transport material | |
EP0915144A1 (en) | Fluorescent liquid crystalline charge transfer materials | |
US7422702B2 (en) | Benzene derivative having long, linear conjugated structure, process for producing benzene derivative, and liquid-crystal material | |
US7390433B2 (en) | Benzene derivative having long, linear conjugated structure, process for producing benzene derivative, and liquid-crystal material | |
JPH05331107A (en) | Antiferroelectric liquid crystal compound | |
Mochizuki et al. | Emission behavior of molecularly doped electroluminescent devices using liquid-crystalline matrices | |
JPH03111486A (en) | Chiral liquid crystal derived from biphenyl | |
JP4574549B2 (en) | Benzene derivative having a long linear conjugated structure, its production method and liquid crystalline material | |
JP2001075297A (en) | Ferroelectric liquid crystalline charge transfer material | |
JPH11144526A (en) | Fluorescent liquid crystalline charge transport material | |
JPH10120629A (en) | Phenyl ester compound and ferridielectric liquid crystal composition containing the same | |
EP0916714A1 (en) | Chiral smectic liquid crystal mixture containing fluoroisoquinolines | |
JP2007063304A (en) | Liquid crystalline composition | |
JPH11199871A (en) | Liquid crystal charge transfer material | |
JP2000068052A (en) | Liquid crystal element drive method | |
JPH05230032A (en) | Liquid crystal compound | |
JPH08253441A (en) | Liquid crystal compound having asymmetric carbon in five-membered ring and liquid crystal composition containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NIPPON CHEMICAL INDUSTRIAL CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HARAMOTO, YUICHIRO;REEL/FRAME:013866/0858 Effective date: 20021118 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
CC | Certificate of correction | ||
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20130104 |